Precision BioSciences, Inc. DTIL
Precision BioSciences, Inc. (Nasdaq: DTIL) is an infectious disease drug developer. Its lead program, PBGENE-HBV, is in Phase 1 for chronic hepatitis B. Its next catalyst on record is PBGENE-DMD: FUNCTION-DMD initial safety data (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PBGENE-DMD — FUNCTION-DMD initial safety data (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PBGENE-HBV | chronic hepatitis B (ELIMINATE-B) | gene therapy | Phase 1 |
| PBGENE-DMD | Duchenne muscular dystrophy (FUNCTION-DMD) | gene therapy | Phase 1 |
Recent results and decisions
- Aug 24, 2026started First patient dosed in August 2026 in the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD at Arkansas Children's Hospital.
today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
Filing - May 27, 2026positive EASL late-breaker: 1-log reduction in cccDNA transcripts in biopsies, durable pgRNA loss in 100% (n=6) with detectable baseline, HBsAg declines in 100% (n=15); 38 doses in 16 patients, no DLTs, one patient with two SAEs (one treatment related, hypotension).
Durable loss of blood pgRNA was demonstrated in 100% of patients treated with PBGENE-HBV (n=6) who had detectable levels pre-treatment (see Figure 3).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.